Successful treatment of cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports

In Vivo

Volumn 23, Issue 3, 2009, Pages 465-468

  Esposito, V ^a   Viglieti, R ^a   Gargiulo, M ^a   Parrella, R ^a   Onofrio, M ^a   Sangiovanni, V ^a   Ambrosino, D ^a   Chirianni, A ^a  

^a AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

Author keywords

C. neoformans; combination therapy; Cryptococcal meningitis; HIV

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPRENAVIR PHOSPHATE; DIURETIC AGENT; EMTRICITABINE; ENFUVIRTIDE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TENOFOVIR;

ADD ON THERAPY; ADULT; ANEMIA; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SUBSTITUTION; FOLLOW UP; HUMAN; INTRACRANIAL HYPERTENSION; MAINTENANCE THERAPY; MALE; NEUTROPENIA; POTASSIUM BLOOD LEVEL; SALVAGE THERAPY; SIDE EFFECT; TREATMENT RESPONSE;

EID: 67649675485     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Saag MS, Graybill RI, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel 3D and Dismukes WE: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 30: 710-718, 2000.
2. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ and Harrison TS: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767, 2004.
3. Barchiesi F, Spreghini E, Schimizzi AM, Maracci M, Giannini D, Cane F and Scalise G: Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 48: 3312-3116, 2004.
4. Najvar LK, Cacciapuoti A, Hernandez S. Halpem J, Bocanegra R, Gurnani M, Menzel F, Loebenberg D and Graybill JR: Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories; Antimicrob Agents Chemother 48: 758-764, 2004.
5. Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R and Loebenberg D: Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 49: 638-642, 2005.
6. Hof H: A new broad spectrum antifungal: posaconazolemechanisms of action and resistance, spectrum of activity. Mycoses 49(Suppl.1): 2-6 2005.
7. Tortes HA, Hacher RY, Chemaly FR, Kontoyiannis DP and Raad II: Posaconazole: a broad spectrum triazole antifungal. Lancet Infect Dis 5: 775-785, 2005.
8. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS and Hardalo CJ: Activity of Posconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56: 745-755, 2005.
9. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU and Fisher JF: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326: 83-89, 1992.
10. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR. Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG and Dismukes WE: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl JMed 337: 15-21, 1997.
11. Perfect JR, Mart KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nubling G, Schlamm HT, Lutsar I, Espinel-Ingroff A and Johnson E: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36: 1122-1131, 2003.
12. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow B, Lister 3 and Anaissie EJ: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26: 1383-1396, 1998.
13. Notheis G, Tarani L, Costantino F, Jansson A, Rosenecker J, Friederici D, Belohradsky BH, Reinhardt P. Seger R, Schweinitz DV and Wintergerst U: Posaconazole for treatment of refractory invasive fungal disease. Mycoses 49(Suppl.1): 37-41, 2006.
14. Rickerts V, Atta J, Henmann S, Jacobi V, Lambrecht E, Bialek R and Just-Nubling G: Successful treatment of disseminated mucormycosis, with a combination of liposomal amphotericin B and posaconazole in a pazient with acute myeloid leukaemia. Mycoses 49(Suppl.1): 27-30, 2006.
15. Dannaoui E, Meletiadis J, Mouton JW, Meis JF and Verweij PB: Eurofung Network; In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51: 45-52, 2003.